FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2111128439> ?p ?o ?g. }

• W2111128439 endingPage "772" @default.
• W2111128439 startingPage "768" @default.
• W2111128439 abstract "Peripheral T-cell lymphoma (PTCL) and natural killer (NK) cell lymphoma have poor survival with conventional cytotoxic chemotherapy. Because angiogenesis plays an important role in the biology of PTCL, a fully humanized anti-vascular endothelial growth factor (VEGF) antibody, bevacizumab (A), was studied in combination with standard cyclosphosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy (ACHOP) to evaluate its potential to improve outcome in these patients. Patients were treated with 6-8 cycles of ACHOP followed by eight doses of maintenance A (15 mg/kg every 21 days). Forty-six patients were enrolled on this phase 2 study from July 2006 through March 2009. Forty-four patients were evaluable for toxicity and 39 were evaluable for response, progression and survival. A total of 324 cycles (range: 2-16, median 7) were administered to 39 evaluable patients and only nine completed all planned treatment. The overall response rate was 90% with 19 (49%) complete response/complete response unconfirmed (CR/CRu) and 16 (41%) a partial response (PR). The 1-year progression-free survival (PFS) rate was 44% at a median follow-up of 3 years. The median PFS and overall survival (OS) rates were 7.7 and 22 months, respectively. Twenty-three patients died (21 from lymphoma, two while in remission). Grade 3 or 4 toxicities included febrile neutropenia (n = 8), anemia (n = 3), thrombocytopenia (n = 5), congestive heart failure (n = 4), venous thrombosis (n = 3), gastrointestinal hemorrhage/perforation (n = 2), infection (n = 8) and fatigue (n = 6). Despite a high overall response rate, the ACHOP regimen failed to result in durable remissions and was associated with significant toxicities. Studies of novel therapeutics are needed for this patient population, whose clinical outcome remains poor." @default.
• W2111128439 created "2016-06-24" @default.
• W2111128439 creator A5003867655 @default.
• W2111128439 creator A5008376801 @default.
• W2111128439 creator A5022982759 @default.
• W2111128439 creator A5025688165 @default.
• W2111128439 creator A5029655862 @default.
• W2111128439 creator A5031758990 @default.
• W2111128439 creator A5060314041 @default.
• W2111128439 creator A5069054551 @default.
• W2111128439 creator A5075568815 @default.
• W2111128439 date "2013-07-29" @default.
• W2111128439 modified "2023-10-05" @default.
• W2111128439 title "Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404)" @default.
• W2111128439 cites W1484238615 @default.
• W2111128439 cites W1501833191 @default.
• W2111128439 cites W1524390400 @default.
• W2111128439 cites W1997550353 @default.
• W2111128439 cites W2005575131 @default.
• W2111128439 cites W2022234182 @default.
• W2111128439 cites W2032102892 @default.
• W2111128439 cites W2037796411 @default.
• W2111128439 cites W2042350838 @default.
• W2111128439 cites W2061524005 @default.
• W2111128439 cites W2061670954 @default.
• W2111128439 cites W2064208261 @default.
• W2111128439 cites W2074643584 @default.
• W2111128439 cites W2088636620 @default.
• W2111128439 cites W2090277718 @default.
• W2111128439 cites W2098666639 @default.
• W2111128439 cites W2131809889 @default.
• W2111128439 cites W2139891818 @default.
• W2111128439 cites W2141235707 @default.
• W2111128439 cites W2145835533 @default.
• W2111128439 cites W2146112074 @default.
• W2111128439 cites W2154965391 @default.
• W2111128439 cites W2157769714 @default.
• W2111128439 cites W2162389158 @default.
• W2111128439 cites W2163510906 @default.
• W2111128439 cites W2171779983 @default.
• W2111128439 doi "https://doi.org/10.3109/10428194.2013.816700" @default.
• W2111128439 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3872505" @default.
• W2111128439 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23786456" @default.
• W2111128439 hasPublicationYear "2013" @default.
• W2111128439 type Work @default.
• W2111128439 sameAs 2111128439 @default.
• W2111128439 citedByCount "39" @default.
• W2111128439 countsByYear W21111284392014 @default.
• W2111128439 countsByYear W21111284392015 @default.
• W2111128439 countsByYear W21111284392016 @default.
• W2111128439 countsByYear W21111284392017 @default.
• W2111128439 countsByYear W21111284392018 @default.
• W2111128439 countsByYear W21111284392019 @default.
• W2111128439 countsByYear W21111284392021 @default.
• W2111128439 countsByYear W21111284392022 @default.
• W2111128439 countsByYear W21111284392023 @default.
• W2111128439 crossrefType "journal-article" @default.
• W2111128439 hasAuthorship W2111128439A5003867655 @default.
• W2111128439 hasAuthorship W2111128439A5008376801 @default.
• W2111128439 hasAuthorship W2111128439A5022982759 @default.
• W2111128439 hasAuthorship W2111128439A5025688165 @default.
• W2111128439 hasAuthorship W2111128439A5029655862 @default.
• W2111128439 hasAuthorship W2111128439A5031758990 @default.
• W2111128439 hasAuthorship W2111128439A5060314041 @default.
• W2111128439 hasAuthorship W2111128439A5069054551 @default.
• W2111128439 hasAuthorship W2111128439A5075568815 @default.
• W2111128439 hasBestOaLocation W21111284392 @default.
• W2111128439 hasConcept C126322002 @default.
• W2111128439 hasConcept C141071460 @default.
• W2111128439 hasConcept C2776694085 @default.
• W2111128439 hasConcept C2776755627 @default.
• W2111128439 hasConcept C2777063308 @default.
• W2111128439 hasConcept C2777802072 @default.
• W2111128439 hasConcept C2778720950 @default.
• W2111128439 hasConcept C2779429289 @default.
• W2111128439 hasConcept C2779725641 @default.
• W2111128439 hasConcept C2781413609 @default.
• W2111128439 hasConcept C71924100 @default.
• W2111128439 hasConcept C90924648 @default.
• W2111128439 hasConceptScore W2111128439C126322002 @default.
• W2111128439 hasConceptScore W2111128439C141071460 @default.
• W2111128439 hasConceptScore W2111128439C2776694085 @default.
• W2111128439 hasConceptScore W2111128439C2776755627 @default.
• W2111128439 hasConceptScore W2111128439C2777063308 @default.
• W2111128439 hasConceptScore W2111128439C2777802072 @default.
• W2111128439 hasConceptScore W2111128439C2778720950 @default.
• W2111128439 hasConceptScore W2111128439C2779429289 @default.
• W2111128439 hasConceptScore W2111128439C2779725641 @default.
• W2111128439 hasConceptScore W2111128439C2781413609 @default.
• W2111128439 hasConceptScore W2111128439C71924100 @default.
• W2111128439 hasConceptScore W2111128439C90924648 @default.
• W2111128439 hasIssue "4" @default.
• W2111128439 hasLocation W21111284391 @default.
• W2111128439 hasLocation W21111284392 @default.
• W2111128439 hasLocation W21111284393 @default.
• W2111128439 hasLocation W21111284394 @default.
• W2111128439 hasOpenAccess W2111128439 @default.
• W2111128439 hasPrimaryLocation W21111284391 @default.

• next